ARKG is trading at $49.55, up 3.21% during the August 25, 2026 session amid continued rotation into healthcare and biotechnology after recent underperformance.
- Rotation is supported by attractive valuations, improving earnings expectations, and renewed dealmaking interest; healthcare funds attracted $2.44 billion in July inflows.
- Broader markets are also modestly higher, with growth stocks leading, helping concentrated biotech holdings recover after ARKG’s August 24 pullback.
- No single August 25 company catalyst clearly explains the move.